Project Grant HT9425261E460
Award Date 9/15/26
Completion Date 9/14/28
Dollars Obligated $963K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pittsburgh, PA 15282, USA
Similar Awards
- The Defense Health Agency awarded the University of Pittsburgh $3.499836 million on July 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to develop a novel nonaddictive analgesic for treating interstitial cystitis/bladder pain syndrome. Performance runs through June 30, 2030, at the University of Pittsburgh's Pittsburgh, Pennsylvania location. The award is classified as a Project Grant and supports basic, applied, and advanced biomedical research to transform...
- The Defense Health Agency awarded the University of Pittsburgh $560,000 on July 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to optimize combination epigenetic drug therapy in sarcomas driven by chromatin derangements. The project runs through June 30, 2028, with performance at the university's Pittsburgh, Pennsylvania campus. This assistance supports basic and applied biomedical research aligned with the Defense Health Program's objective to transform...
- The Defense Health Agency awarded the University of Pittsburgh $1,462,665 on July 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to investigate the intratumoral microbiome in acral melanoma. The three-year project runs through June 30, 2029, and is performed in Pittsburgh, Pennsylvania. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform health care for Service Members and the American...
- The Defense Health Agency awarded New York University School of Medicine $833,334 on September 30, 2026, under the Military Medical Research and Development program (CFDA 12.420) to identify pathways that prevent the emergence of drug-tolerant persisters. The award supports basic and applied biomedical research with a period of performance through September 29, 2029, and work will be performed in New York, New York. The Military Medical Research and Development program funds R&D assistance...
- The Defense Health Agency awarded New York University School of Medicine $1.666 million on September 30, 2026, under the Military Medical Research and Development program (CFDA 12.420) to identify pathways that prevent the emergence of drug-tolerant persisters. The award supports basic and applied biomedical research intended to transform health care for Service Members and the American public through innovative and impactful research. Work will be performed in New York, New York, with a...
- The Defense Health Agency awarded Wake Forest University Health Sciences $621,779 on April 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to investigate modulating immune stress pathways as a strategy for chemotherapy-induced peripheral neuropathy prevention and cancer management. The project runs through March 31, 2029, with performance in Winston-Salem, North Carolina. The Military Medical Research and Development program supports basic, applied, and...
- The Defense Health Agency awarded The Washington University $140,000 on September 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to identify small molecules targeting the P14ARF pathway to treat CDKN2A-deficient malignant peripheral nerve sheath tumor. Work is performed in University City, Missouri, with a period of performance through August 31, 2028. The award is structured as a Project Grant, a common assistance type within the Defense Health Program's...
- The Defense Health Agency awarded New York University School of Medicine $750,962 on June 15, 2026, under the Military Medical Research and Development program (CFDA 12.420) to investigate neoadjuvant checkpoint and IL-6 blockade mechanisms of benefit and toxicity. The award supports basic and applied biomedical research with a period of performance through June 14, 2029. Work is performed in New York, New York. The Military Medical Research and Development program funds research to transform...
- The Defense Health Agency awarded the University of Pittsburgh $1.8 million on May 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to investigate mechanisms and develop innovative therapies for ESR1-CCDC170 fusions in clinically aggressive, endocrine-resistant, and metastatic breast cancers. The award supports a three-year project period ending April 30, 2029, with work performed at the University of Pittsburgh in Pittsburgh, Pennsylvania. The Military...
- The Defense Health Agency awarded Wake Forest University Health Sciences $627,944 on April 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to support research on modulating immune stress pathways as a strategy for chemotherapy-induced peripheral neuropathy (CIPN) prevention and cancer management. Work will be performed in Winston-Salem, North Carolina, with a period of performance ending March 31, 2029. The source does not specify sub-recipients,...